The antibiotic azithromycin reduced low birth weight and prematurity in Africa and Asia but didn’t lower infant deaths, infections or hospital admissions, a research review1 has found. In a systematic review and meta-analysis, researchers led by the Murdoch Children’s Research Institute (MCRI) reviewed 14 studies undertaken in African and Asian countries, involving 17,594 participants. This review found that there was uncertainty about the potential benefits of this intervention on neonatal deaths, admissions and infections, and potential harmful effects on stillbirth despite biological reasons why this intervention may have benefits for these outcomes.
Amyloid protein produced in the liver can cause neurodegeneration in brain tissue, a new study1 by John Mamo of Curtin University, and colleagues has found. Since the protein is thought to be a key contributor to development of Alzheimer’s disease (AD), the results suggest that the liver may play an important role in the onset or progression of the disease. Deposits of amyloid beta (A-beta) in the brain are one of the pathological hallmarks of AD and are implicated in neurodegeneration in both human patients and animal models of the disease.
Parents and grandparents of individuals with Attention-deficit/hyperactivity disorder were at higher risk of dementia than those with children and grandchildren without ADHD, a large study1 at Karolinska Institutet in Sweden has found. The findings suggest that there are common genetic and/or environmental contributions to the association between ADHD and dementia. Now we need further studies to understand the underlying mechanisms," said first author Le Zhang, Ph.D. student at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) have developed a software program - called ModTect - that can help reveal the relationships between RNA modifications and the development of diseases and disorders. Led by Professor Daniel Tenen and Dr Henry Yang, the scientists carried out their own novel pan-cancer study1 covering 33 different cancer types. This work is one of few studies demonstrating the association of mRNA modification with cancer development.
Rovalpituzumab tesirine (Rova-T) is not effective against small-cell lung cancer (SCLC), four independent studies show. SCLC remains a difficult disease to treat, especially at the time of relapse. Currently, topotecan is among the most effective treatments, but it is not the most desirable and favored drug in the second-line setting because of its toxicity profile. Still, it has been difficult for new agents to “beat” this drug in the second-line setting.
Antibody-drug conjugates (ADCs) are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs. Schematic structure of an antibody-drug conjugate (ADC). Credit: CC-BY Antibody-drug conjugates are complex molecules composed of an antibody linked to a biologically anticancer payload or drug.
A minimally invasive electrode brain implant evoked the sense of touch in a first-in-human study from The Feinstein Institutes for Medical Research. The work1 could potentially help millions of people who live with paralysis and neuropathy. From buttoning our shirts to holding a loved one’s hand, our sense of touch may be taken for granted until we lose it. These results show the ability to generate that sensation, even after it is lost, which may lead us to a clinical option in the future,
Gemtuzumab ozogamicin (brand name Mylotarg), is an antibody-drug conjugate used to treat acute myeloid leukemia. Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of stem cells. Mylotarg Side Effects The most common grade 3 and higher adverse reactions that occurred during Induction 1 and Intensification 2 in ≥ 5% of people who received gemtuzumab ozogamicin were infection, febrile neutropenia, decreased appetite, hyperglycemia, mucositis, hypoxia, hemorrhage, increased transaminase, diarrhea, nausea, and hypotension.